Category: Subarachnoid hemorrhage

Following an aneurysmal subarachnoid hemorrhage (aSAH), patients are at significant risk of delayed cerebral ischemia (DCI), a leading cause of severe disability and mortality. The standard of care to mitigate this risk involves a specific CCB: Nimodipine.

Subarachnoid hemorrhage (SAH) is a devastating type of stroke, with approximately 55% of patients being under the age of 55 when the event occurs. The primary pharmacological intervention used to manage this condition is nimodipine, answering the critical question: what is the drug of choice for subarachnoid hemorrhage? This calcium channel blocker is a cornerstone of treatment, aiming to improve neurological outcomes and prevent complications.